Functional and physical communication between oncoproteins and tumor suppressors

Cellular and Molecular Life Sciences

Volumn 62, Issue 21, 2005, Pages 2438-2459

  Prochownik, E V ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

CIN; Cyclins; E2F; Fanconi's anemia; Genomic instability; MIN; Myc; p53, Rb; Peroxiredoxin

Indexed keywords

ALPHA TOCOPHEROL; APC PROTEIN; ASCORBIC ACID; CAROTENOID; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE; CYCLIN E; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MISMATCH REPAIR PROTEIN PMS2; MIXED LINEAGE KINASE 3; ONCOPROTEIN; PEROXIREDOXIN; PROTEIN KINASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN; SELENIUM; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

CANCER; DNA DAMAGE; EXCISION REPAIR; GENE INACTIVATION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; MISMATCH REPAIR; NONHUMAN; ONCOGENE C MYC; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CELL COMMUNICATION; HUMANS; MUTATION; ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 29144504350     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-005-5199-8     Document Type: Review

References (180)

1. Stehelin D., Varmus H. E., Bishop J. M. and Vogt P.K. (1976) DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260: 170-173
2. Bishop J. M. (1983) Cellular oncogenes and retroviruses. Annu. Rev. Biochem. 52: 301-354
3. Hayward W. S., Neel B. G. and Astrin S. M. (1981) Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 290: 475-480
4. Weinberg R. A. (1983) Transforming genes of tumor cells. Int. Rev. Cytol. Suppl. 15: 191-202
5. Sukumar S., Notario V., Martin-Zanca D. and Barbacid M. (1983) Induction of mammary carcinomas in rats by nitrosomethylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature 306: 658-661
6. Nesbit C. E., Tersak J. M. and Prochownik E. V. (1999) MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016
7. Harris H., Miller O. J., Klein G., Worst P. and Tachibana T. (1969) Suppression of malignancy by cell fusion. Nature 223: 363-368
8. Knudson A. G. Jr (1976) Genetics and the etiology of childhood cancer. Pediatr. Res. 10: 513-517
9. Friend S. H., Bernards R., Rogelj S., Weinberg R. A., Rapaport J. M., Albert D. M. et al. (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 323: 643-646
10. Oren M. and Levine A. J. (1983) Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc. Natl. Acad. Sci. USA 80: 56-59
11. Land H., Parada L. F. and Weinberg R. A. (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304: 596-602
12. Sherr C. J. (2004) Principles of tumor suppression. Cell 116: 235-246
13. Nevins J. R. (2001) The Rb/E2F pathway and cancer. Hum. Mol. Genet. 10: 699-703
14. Chau B. N. and Wang J. Y. (2003) Coordinated regulation of life and death by RB. Nat. Rev. Cancer 3: 130-138
15. Classon M. and Harlow E. (2002) The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2: 910-917
16. Frolov M. V. and Dyson N. J. (2004) Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J. Cell. Sci. 117: 2173-2181
17. Vousden K. H. (2002) Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta 1602: 47-59
18. Kalma Y., Marash L., Lamed Y. and Ginsberg D. (2001) Expression analysis using DNA microarrays demonstrates that E2F-1 up-regulates expression of DNA replication genes including replication protein A2. Oncogene 20: 1379-1387
19. Muller H., Bracken A. P., Vernell R., Moroni M. C., Christians F., Grassilli E. et al. (2001) E2Fs regulate the expression of genes involved in differentiation, development, proliferation and apoptosis. Genes Dev. 15: 267-285
20. Harbour J. W. and Dean D. C. (2000) The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14: 2393-3409
21. Sherr C. J. and Roberts J. M. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13: 1501-1512
22. Bates S. and Peters G. (1995) Cyclin D1 as a cellular proto-oncogene. Semin. Cancer Biol. 6: 73-82
23. Xia S. J., Pressey J. G. and Barr F. G. (2002) Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol. Ther. 1: 97-104
24. Liggett W. H. Jr and Sidransky D. (1998) Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol. 16: 1197-1206
25. Johnson D. G., Cress W. D., Jakoi L. and Nevins J. R. (1994) Oncogenic capacity of the E2F1 gene. Proc. Natl. Acad. Sci. USA 91: 12823-12827
26. Adams P. D. and Kaelin W. G. Jr (1996) The cellular effects of E2F overexpression. Curr. Top. Microbiol. Immunol. 208: 79-93
27. Lane D. P. (1992) p53, guardian of the genome. Nature 358: 15-16
28. Vousden K. H. and Lu X. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer. 2: 594-604
29. Quelle D. E., Zindy F., Ashmun R. A. and Sherr C. J. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000
30. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
31. Bartek J. and Lukas J. (2001) Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 490: 117-122
32. Afshari C. A., Nichols M. A., Xiong Y. and Mudryj M. (1996) A role for a p21-E2F interaction during senescence arrest of normal human fibroblasts. Cell Growth Differ. 7: 979-988
33. Lowe S. W. and Sherr C. J. (2003) Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13: 77-83
34. Maeda T., Hobbs R. M., Merghoub T., Guernah I., Zelent A., Cordon-Cardo C. et al. (2005) Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433: 278-285
35. Haas K., Johannes C., Geisen C., Schmidt T., Karsunky H., Blass-Kampmann S. et al. (1997) Malignant transformation by cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4. Oncogene 15: 2615-2623
36. Ortega S., Malumbres M. and Barbacid M. (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 1602: 73-87
37. Wingate H., Zhang N., McGarhen M. J., Bedrosian I., Harper J. W. and Keyomarsi K. (2005) The tumor specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J. Biol. Chem, in press
38. Stewart T. A., Pattengale P. K. and Leder P. (1984) Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38: 627-637
39. Sinn E., Muller W., Pattengale P., Tepler I., Wallace R. and Leder P. (1987) Coexpression of MMTV/v-Ha-ras and MMTV/ c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49: 465-475
40. Kinzler K. W. and Vogelstein B. (1996) Lessons from hereditary colorectal cancer. Cell 87: 159-170
41. Hanahan D. and Weinberg R. A. (2000) The hallmarks of cancer. Cell 100: 57-70
42. Hahn W. C. and Weinberg R. A. (2002) Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2: 331-341
43. Loeb L. A., Springgate C. F. and Battula N. (1974) Errors in DNA replication as a basis of malignant changes. Cancer Res. 34: 2311-2321
44. Risinger M. A. and Groden J. (2004) Crosslinks and crosstalk: human cancer syndromes and DNA repair defects. Cancer Cell 6: 539-545
45. Loeb L. A., Loeb K. R. and Anderson J. P. (2003) Multiple mutations and cancer. Proc. Natl. Acad. Sci. USA 100: 776-781
46. Kinzler K. W. and Vogelstein B. (1997) Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761, 763
47. Goldsby R. E., Lawrence N. A., Hays L. E., Olmsted E. A., Chen X., Singh M. et al. (2001) Defective DNA polymerase-delta proofreading causes cancer susceptibility in mice. Nat. Med. 7: 638-639
48. Kramer A, Neben K. and Ho A. D. (2002) Centrosome replication, genomic instability and cancer. Leukemia 16: 767-775
49. Brentnall T. A., Chen R., Lee J. G., Kimmey M. B., Bronner M. P., Haggitt R. C. et al. (1995) Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res. 55: 4264-4267
50. Brentnall T. A., Crispin D. A., Bronner M. P., Cherian S. P., Hueffed M., Rabinovitch P. S. et al. (1996) Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 56: 12337-12340
51. Lu N., Hu N., Li W. J., Roth M. J., Wang C., Su H. et al. (2003) Microsatellite alterations in esophageal dysplasia and squamous cell carcinoma from laser capture microdissected endoscopic biopsies. Cancer Lett. 189: 137-145
52. Chung D. C. and Rustgi A. K. (2003) The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann. Intern. Med. 138: 560-570
53. Yao X., Buermeyer A. B., Narayanan L., Tran D., Baker S. M., Prolla T. A. et al. (1999) Different mutator phenotypes in Mlh1-versus Pms2-deficient mice. Proc. Natl. Acad. Sci. USA 96: 6850-6855
54. Reitmair A. H., Schmits R., Ewel A., Bapat B., Redston M., Mitri A. et al. (1995) MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat. Genet. 11: 64-70
55. Toft N. J., Winton D. J., Kelly J., Howard L. A., Dekker M., te Riele H. et al. (1999) Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc. Natl. Acad. Sci. USA 96: 3911-3915
56. Hofseth L. J., Khan M. A., Ambrose M., Nikolayeva O., XuWelliver M., Kartalou M. et al. (2003) The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J. Clin. Invest. 112: 1887-1894
57. Spencer F., Gerring S. L., Connelly C. and Hieter P. (1990) Mitotic chromosome transmission fidelity mutants in Saccharomyces cerevisiae. Genetics 124: 237-249
58. Shih I. M., Zhou W., Goodman S. N., Lengauer C., Kinzler K. W. and Vogelstein B. (2001) Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res. 61: 818-822
59. Luft F., Gebert J., Schneider A., Melsheimer P. and von Knebel Doeberitz M. (1999) Frequent allelic imbalance of tumor suppressor gene loci in cervical dysplasia. Int. J. Gynecol. Pathol. 18: 374-380
60. Rubin C. E., Haggitt R. C., Burmer G. C., Brentnall T. A., Stevens A. C., Levine D. S. et al. (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103: 1611-1620
61. Tan A. L., Rida P. C. and Surana U. (2005) Essential tension and constructive destruction: the spindle checkpoint and its regulatory links with mitotic exit. Biochem. J. 386: 1-13
62. Acquaviva C., Herzog F., Kraft C. and Pines J. (2004) The anaphase promoting complex/cyclosome is recruited to centromeres by the spindle assembly checkpoint. Nat. Cell Biol. 6: 892-898
63. Rieder C. L. and Maiato H. (2004) Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell. 7: 637-651
64. Taylor S. S., Hussein D., Wang Y., Elderkin S. and Morrow C. J. (2001) Kinetochore localisation and phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are differentially regulated by spindle events in human cells. J. Cell Sci. 114: 4385-4395
65. Howell B. J., Moree B., Farrar E. M., Stewart S., Fang G. and Salmon E. D. (2004) Spindle checkpoint protein dynamics at kinetochores in living cells. Curr. Biol. 14: 953-964
66. Meraldi P., Draviam V. M. and Sorger P. K. (2004) Timing and checkpoints in the regulation of mitotic progression. Dev. Cell. 7: 45-60
67. Jallepalli P. V., Waizenegger I. C., Bunz F., Langer S., Speicher M. R., Peters J. M. et al. (2001) Securin is required for chromosomal stability in human cells. Cell 105: 445-457
68. Arnaud L., Pines J. and Nigg E. A. (1998) GFP tagging reveals human Polo-like kinase 1 at the kinetochore/centromere region of mitotic chromosomes. Chromosoma 107: 424-429
69. Alexandru G., Uhlmann F., Mechtler K., Poupart M. A. and Nasmyth K. (2001) Phosphorylation of the cohesin subunit Scc1 by Polo/Cdc5 kinase regulates sister chromatid separation in yeast. Cell 105: 459-472
70. Dai W., Wang Q., Liu T., Swamy M., Fang Y., Xie S. et al. (2004) Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res. 64: 440-445
71. Michel L. S., Liberal V., Chatterjee A., Kirchwegger R., Pasche B., Gerald W et al. (2001) MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409: 355-359
72. Cahill D. P., Lengauer C., Yu J., Riggins G. J., Willson J. K., Markowitz S. D. et al. (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 1392: 300-303
73. Jallepalli P. V. and Lengauer C. (2001) Chromosome segregation and cancer: cutting through the mystery. Nat. Rev. Cancer 1: 109-117
74. Pei L. and Melmed S. (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 11: 433-441
75. Hanks S., Coleman K., Reid S., Plaja A., Firth H., Fitzpatrick D. et al. (2004) Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat. Genet. 36: 1159-1161
76. Vogelstein B. and Kinzler K. W. (2004) Cancer genes and the pathways they control. Nat. Med. 10: 789-799
77. Clevers H. (2004) Wnt breakers in colon cancer. Cancer Cell 5: 5-6
78. Yin X. Y., Grove L., Datta N. S., Long M. W. and Prochownik E. V. (1999) C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene 18: 1177-1184
79. Karlsson A., Deb-Basu D., Cherry A., Turner S., Ford J. and Felsher D/W. (2003) Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc. Natl. Acad. Sci. USA 100: 9974-9979
80. Fodde R., Kuipers J., Rosenberg C., Smits R., Kielman M., Gaspar C. et al. (2001) Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat. Cell Biol. 3: 433-438
81. Kaplan K. B., Burds A. A., Swedlow J. R., Bekir S. S., Sorger P. K. and Nathke I. S. (2001) A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Cell Biol. 3: 429-432
82. Berrueta L., Kraeft S. K., Tirnauer J. S., Schuyler S. C., Chen L. B., Hill D. E. et al. (1998) The adenomatous polyposis coli-binding protein EB1 is associated with cytoplasmic and spindle microtubules. Proc. Natl. Acad. Sci. USA 95: 10596-10601
83. Emdad L., Sarkar D., Su Z. Z. and Fisher P. B. (2005) Emerging roles of centrosomal amplification and genomic instability in cancer. Front Biosci. 10: 728-742
84. Fukasawa K., Wiener F., Vande Woude G. F. and Mai S. (1997) Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 15: 1295-1302
85. Tarapore P. and Fukasawa K. (2002) Loss of p53 and centrosome hyperamplification. Oncogene 21: 6234-6240
86. Morris V. B., Brammall J., Noble J. and Reddel R. (2000) p53 localizes to the centrosomes and spindles of mitotic cells in the embryonic chick epiblast, human cell lines and a human primary culture: an immunofluorescence study. Exp. Cell Res. 256: 122-130
87. Bennett R. A., Izumi H. and Fukasawa K. (2004) Induction of centrosome amplification and chromosome instability in p53-null cells by transient exposure to subtoxic levels of S-phase-targeting anticancer drugs. Oncogene 23: 6823-6829
88. Patel D., Incassati A., Wang N. and McCance D. J. (2004) Human papillomavirus type 16 E6 and E7 cause polyploidy in human keratinocytes and up-regulation of G2-M-phase proteins. Cancer Res. 64: 1299-1306
89. Lotti L. V., Ottini L., D'Amico C., Gradini R., Cama A., Belleudi F. et al. (2002) Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 35: 193-203
90. Wang R. H., Yu H. and Deng C. X. (2004) A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc. Natl. Acad. Sci. USA 101: 17108-17113
91. Jeang K. T., Giam C. Z., Majone F. and Aboud M. (2004) Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J. Biol. Chem. 279: 31991-31994
92. Liu B., Liang M. H., Kuo Y. L., Liao W., Boros I., Kleinberger T. et al. (2003) Human T-lymphotropic virus type 1 oncoprotein tax promotes unscheduled degradation of Pds1p/securin and Clb2p/cyclin B1 and causes chromosomal instability. Mol. Cell Biol. 23: 5269-5281
93. Liu B., Hong S., Tang, Z., Yu, H. and Giam C-Z. (2005) HTLV-I Tax directly binds the Cdc20-associated anaphase-promoting complex and activates it ahead of schedule. Proc. Natl. Acad. Sci. USA 102: 63-68
94. Yin X. Y., Grove L., Datta N. S., Katula K., Long M. W. and Prochownik E. V. (2001) Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res. 61: 6487-6493
95. Sarafan-Vasseur N., Lamy A., Bourguignon J., Pessot F. L., Hieter P., Sesboue R. et al. (2002) Overexpression of B-type cyclins alters chromosomal segregation. Oncogene 21: 2051-2057
96. Moore J. D., Kirk J. A. and Hunt T. (2003) Unmasking the S-phase-promoting potential of cyclin B1. Science 300: 987-990
97. Iacopetta B. (2002) Are there two sides to colorectal cancer? Int. J. Cancer 101: 403-408
98. ryfe R., Kim H., Hsieh E. ., Aronson M.D., Holowaty E. ., Bull S. . et al. (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342: 69-77
99. Hemminki A., Mecklin J. P., Jarvinen H., Aaltonen L. A. and Joensuu H. (2000) Chromosomal instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119: 921-928
100. Elsaleh H., Powell B., McCaul K., Grieu F., Grant R. and Joseph D. et al. (2001) p53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin. Cancer Res. 7: 1343-1349
101. Dunican D. S., McWilliam P., Tighe O., Parle-McDermott A. and Croke D.T. (2002) Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene 21: 3253-3257
102. Marnett L. J., Riggins J. N. and West J. D. (2003) Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J. Clin. Invest. 111: 583-593
103. Cooke M. S., Evans M. D., Dizdaroglu M.and Lunec J. (2003) Oxidative DNA damage: mechanisms, mutation and disease. FASEB J. 7: 1195-1214
104. Loft S. and Poulsen H. E. (1996) Cancer risk and oxidative DNA damage in man. J. Mol. Med. 74: 297-312
105. Henderson C. J., Smith A. G., Ure J., Brown K., Bacon E. J. and Wolf C. R. (•) Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc. Natl. Acad. Sci. USA 95: 5275-5280
106. Ramos-Gomez M., Kwak M. K., Dolan P. M., Itoh K., Yamamoto M., Talalay P. et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. USA 98: 3410-3415
107. Neumann C. A., Krause D. S., Carman C. V., Das S., Dubey D. P., Abraham J. L. et al. (2003) Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424: 561-565
108. Egler, R. A., Fernandes, E., Rothermund, K., Sereika, S., deSouza-Pinho, N., Jaruga, P. et al. Regulation of reactive oxygen species. DNA damage, and c-Myc function by peroxiredoxin I. Oncogene, in press
109. Noh D. Y., Ahn S. J., Lee R. A., Kim S.W., Park I. A. and Chae H. Z. (2001) Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 21: 2085-2090
110. Yanagawa T., Iwasa S., Ishii T., Tabuchi K., Yusa H., Onizawa K. et al. (2000) Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 156: 27-35
111. Sulman E. P., White P. S. and Brodeur G. M. (2004) Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34. Oncogene 23: 1014-1020
112. Wen S. T. and Van Etten R. A. (1997) The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11: 2456-2467
113. Mu Z. M., Yin X. Y. and Prochownik E. V. (2002) Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J. Biol. Chem. 277: 43175-43184
114. Li B., Wang X., Rasheed N., Hu Y., Boast S., Ishii T. et al. (2004) Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev. 18: 1824-1837
115. Nesbit C. E., Tersak J. M., Grove L. E., Drzal A., Choi H. and Prochownik E. V. (2000) Genetic dissection of c-myc apoptotic pathways. Oncogene 19: 3200-3212
116. Vafa O., Wade M., Kern S., Beeche M., Pandita T. K., Hampton G. M. et al. (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability.Mol. Cell. 9: 1031-1044
117. Al-Tassan N., Chmiel N. H., Maynard J., Fleming N., Livingston A. L., Williams G. T. et al. (2002) Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat. Genet. 30: 227-232
118. Gu Y., Parker A., Wilson T. M., Bai H., Chang D. Y. and Lu A. L. (2002) Human MutY homolog, a DNA glycosylase involved in base excision repair, physically and functionally interacts with mismatch repair proteins human MutS homolog 2/human MutS homolog 6. J. Biol. Chem. 277: 11135-11142
119. Fernandez P. C., Frank S. R., Wang L., Schroeder M., Liu S., Greene J. et al. (2003) Genomic targets of the human c-Myc protein. Genes Dev. 17: 1115-1129
120. Patel J. H., Loboda A. P., Showe M. K., Showe L. C. and McMahon S. B. (2004) Analysis of genomic targets reveals complex functions of MYC. Nat. Rev. Cancer 4: 562-568
121. Davis A. C., Wims M., Spotts G. D., Hann S. R. and Bradley A. (1993) A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev. 7: 671-682
122. Oster S. K., Ho C. S., Soucie E. L. and Penn L. Z. (2002) The myc oncogene: MarvelouslY Complex. Adv. Cancer Res. 84: 81-154
123. Blackwood E. M. and Eisenman R. N. (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1211-1217
124. Baudino T. A. and Cleveland J. L. (2001) The Max network gone mad. Mol. Cell. Biol. 21: 691-702
125. Nair S. K. and Burley S. K. (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112: 193-205
126. McMahon S. B., Van Buskirk H. A., Dugan K. A., Copeland T. D. and Cole M. D. (1998) The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94: 363-374
127. Dugan K. A., Wood M. A. and Cole M. D. (2002) TIP49, but not TRRAP, modulates c-Myc and E2F1 dependent apoptosis. Oncogene 21: 5835-5843
128. Nikiforov M. A., Chandriani S., Park J., Kotenko I., Matheos D., Johnsson A. et al. (2002) TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins. Mol. Cell. Biol. 22: 5054-5063
129. Frank S. R., Parisi T., Taubert S., Fernandez P., Fuchs M., Chan H. M. et al. (2003) MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 4: 575-580
130. Wood M. A., McMahon S. B. and Cole M. D. (2000) An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol. Cell 5: 321-530
131. McMahon S. B., Wood M. A. and Cole M. D. (2000) The essential cofactor TRRAP recruits the histone acetyltransferase hGCNS to c-Myc. Mol. Cell. Biol. 20: 556-562
132. Park J., Kunjibettu S., McMahon S. B. and Cole M. D. (2001) The ATM-related domain of TRRAP is required for histone acetyltransferase recruitment and Myc-dependent oncogenesis. Genes Dev. 15: 1619-1624
133. Eisenman R. N. (2001) Deconstructing myc. Genes Dev. 15: 2023-2030
134. Patel J. H., Du Y., Ard P. G., Phillips C., Carella B., Chen C. J. et al. (2004) The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol. Cell. Biol. 24: 10826-10834
135. Biegel J. A., Tan L., Zhang F., Wainwright L., Russo P. and, Rorke L. B. (2002) Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin. Cancer Res. 8: 3461-3467
136. DeCristofaro M. F., Betz B. L., Wang W. and Weissman B. E. (1999) Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. Oncogene 18: 7559-7565
137. Uno K., Takita J., Yokomori K., Tanaka Y., Ohta S., Shimada H. et al. (2002) Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.Genes Chromosomes Cancer 34: 33-41
138. Muchardt C. and Yaniv M. (2001) When the SWI/SNF complex remodels ... the cell cycle. Oncogene 20: 3067-3075
139. ang W., Cote J., Xue Y., Zhou S., Khavari P. ., Biggar S. . et al. (1996) Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 5: 5370-5382
140. Cheng S. W., Davies K. P., Yung E., Beltran R. J., Yu J. and Kalpana G. V. (1999) c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat. Genet. 22: 102-105
141. Roberts C. W., Leroux M. M., Fleming M. D. and Orkin S. H. (2002) Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2: 415-425
142. Dunaief J. L., Strober B. E., Guha S., Khavari P. A., Alin K., Luban J. et al. (1994) The retinoblastema protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 79: 119-130
143. Otsuki T., Furukawa Y., Ikeda K., Endo H., Yamashita T., Shinohara A. et al. (2001) Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex. Hum. Mol. Genet. 10: 2651-2660
144. Venkitaraman A. R. (2004) Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat. Rev. Cancer 4: 266-276
145. Wang X. and D'Andrea A. D. (2004) The interplay of Fanconi anemia proteins in the DNA damage response. DNA Repair (Amst) 3: 1063-1069
146. Pagano G. and Youssoufian H. (2003) Fanconi anaemia proteins: major roles in cell protection against oxidative damage. Bioessays 25: 589-595
147. Qi Y., Gregory M. A., Li Z., Brousal J. P., West K. and Hann S. R. (2004) p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431: 712-717
148. Eischen C. M., Weber J. D., Roussel M. F., Sherr C. J. and Cleveland J. L. (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13: 2658-2669
149. Jacobs J. J., Scheijen B., Voncken J. W., Kieboom K., Berns A. and van Lohuizen M. (1999) Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13: 2678-2690
150. Yin X., Landay M. F., Han W., Levitan E. S., Watkins S. C., Levenson R. M. et al. (2001) Dynamic in vivo interactions among Myc network members. Oncogene 20: 4650-4664
151. Grinberg A. V., Hu C. D. and Kerppola T. K. (2004) Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells. Mol. Cell. Biol. 24: 4294-4308
152. Vousden K. H. (2000) p53: death star. Cell 103: 691-694
153. Sakamuro D., Elliott K. J., Wechsler-Reya R. and Prendergast G. C. (1996) BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat. Genet. 14: 69-77
154. DuHadaway J. B., Lynch F. J., Brisbay S., Bueso-Ramos C., Troncoso P., McDonnell T. et al. (2003) Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J. Cell. Biochem. 88: 635-642
155. Elliott K., Sakamuro D., Basu A., Du W., Wunner W., Staller P. et al. (1999) Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene 18: 3564-3573
156. Galderisi U., Di Bernardo G., Cipollaro M., Jori F. P., Piegari E., Cascino A. et al. (1999) Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel Myc interacting protein. J. Cell. Biochem. 74: 313-322
157. Ge K., Minhas F., Duhadaway J., Mao N. C., Wilson D., Buccafusca R. et al. (2000) Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int. J. Cancer. 86: 155-161
158. Ge K., Duhadaway J., Sakamuro D., Wechsler-Reya R., Reynolds C. and Prendergast G. C. (2000) Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int. J. Cancer. 85: 376-383
159. Tajiri T., Liu X., Thompson P. M., Tanaka S., Suita S., Zhao H. et al. 2003) Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin. Cancer Res. 9: 3345-3355
160. Muller A. J., Baker J. F., DuHadaway J. B., Ge K., Farmer G., Donover P. S. et al. (2003) Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol. Cell. Biol. 23: 4295-4306
161. Dang C. V. (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19: 1-11
162. Gomez-Roman N., Grandori C., Eisenman R. N. and White R. J. (2003) Direct activation of RNA polymerase III transcription by c-Myc. Nature 421: 290-294
163. Felton-Edkins Z. A., Kenneth N. S., Brown T. R., Daly N. L., Gomez-Roman N., Grandori C. et al. (2003) Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc. Cell Cycle 2: 181-184
164. Adnane J. and Robbins P. D. (1995) The retinoblastoma susceptibility gene product regulates Myc-mediated transcription. Oncogene 10: 381-387
165. Gu W., Bhatia K., Magrath I. T., Dang C. V. and Dalla-Favera R. (1994) Binding and suppression of the Myc transcriptional activation domain by p107. Science 264: 251-254
166. Grandori C., Cowley S. M., James L. P. and Eisenman R. N. (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16: 653-699
167. Foley K. P. and Eisenman R. N. (1999) Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. Biophys. Acta 1423: M37-47
168. Queva C., McArthur G. A., Iritani B. M. and Eisenman R. N. (2001) Targeted deletion of the S-phase-specific Myc antagonist Mad3 sensitizes neuronal and lymphoid cells to radiation-induced apoptosis. Mol. Cell. Biol. 21: 703-712
169. Schreiber-Agus N., Meng Y., Hoang T., Hou H. Jr, Chen K., Greenberg R. et al. (1998) Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 393: 483-187
170. Toyo-oka K., Hirotsune S., Gambello M. J., Zhou Z. Q., Olson L., Rosenfeld M. G. et al. (2004) Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome. Hum. Mol. Genet. 13: 1057-1067
171. Hurlin P. J., Zhou Z. Q., Toyo-oka K., Ota S., Walker W. L., Hirotsune S. et al. (2003) Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis. EMBO J. 22: 4584-4596
172. Nilsson J. A., Maclean K. H., Keller U. B., Pendeville H., Baudino T. A. and Cleveland J. L. (2004) Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol. Cell. Biol. 24: 1560-1569
173. Eagle L. R., Yin X., Brothman A. R., Williams B. J., Atkin N. B. and Prochownik E. V. (1995) Mutation of the MXI1 gene in prostate cancer. Nat. Genet. 9: 249-255
174. Prochownik E. V., Eagle-Grove L., Deubler D., Zhu X. L., Stephenson R. A., Rohr L. R. et al. (1998) Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 22: 295-304
175. Ariyanayagam-Baksh S. M., Baksh F. K., Swalsky P. A. and Finkelstein S. D. (2003) Loss of heterozygosity in the MXI1 gene is a frequent occurrence in melanoma. Mod. Pathol. 16: 992-995
176. Santarosa M. and Ashworth A. (2004) Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim. Biophys. Acta 1654: 105-122
177. Bond G. L., Hu W., Bond E. E., Robins H., Lutzker S. G., Arva N. C. et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602
178. Prendergast G. C. (1999) Mechanisms of apoptosis by c-Myc. Oncogene 18: 2967-2987
179. Tweddle D. A., Pearson A. D., Haber M., Norris M. D., Xue C., Flemming C. et al. (2003) The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 197: 93-98
180. Slack A., Chen Z., Tonelli R., Pule M., Hunt L., Pession A. et al. (2005) The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc. Natl. Acad. Sci. USA 102: 731-736